comprehensive -WSS

comprehensive

author：fashion 2025-08-12 08:29:34 - browse：672

Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble — coverage from STAT — Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble. Adobe

An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some signs of efficacy in prostate cancer patients, newly released data show, but four participants in the trial died.

The drug, JNJ-6420, is designed to treat metastatic castration-resistant prostate cancer by delivering radioactive isotopes directly to cancer cells. Interest in such radiopharmaceuticals has skyrocketed following the approval of Pluvicto, which also treats prostate cancer.

In the Phase 1 data reported ahead of the American Society of Clinical Oncology meeting next week, 18% of participants on a mid-level dose of Johnson & Johnson’s treatment had a complete or partial response. For comparison, approximately 29.8% of the subjects in a Phase 3 trial of Pluvicto responded to the treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： FDA approval of Sarepta Duchenne genetic therapy gives me hope

explore

WSS

Experts study whether long Covid risk adds up with each reinfection

The biotech scorecard for Q4: 16 stock

Supreme Court strikes down use of affirmative action

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

ChatGPT in medicine: STAT answers readers' burning questions

FDA approval of Sarepta Duchenne genetic therapy gives me hope

leisure time

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

How to save PrEP access — and even expand it

Hollywood unions extend contract negotiations for actors

Congress extends some pandemic preparedness programs

FDA approval of Sarepta Duchenne genetic therapy gives me hope

WHO recommends second malaria vaccine

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Wildfire smoke exposes gaps in outdoor worker protections

Anesthesiologist group: stop taking Ozempic before surgery

6 solutions to address cancer drug shortages and others

hotspot

Moonlake's readout produced a cash windfall. Risks remain

Study points to new risk in gene therapy death of Terry Horgan

Congress extends some pandemic preparedness programs

Stop Congress from blocking public access to science

The cancer drug shortage isn’t new — and neither are the solutions

Anesthesiologist group: stop taking Ozempic before surgery

hotspot

hotspot

explore

leisure time